PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism.
PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism.
复制标题
PD-1/PD-L1 抑制剂相关性心肌炎：流行病学、特征、诊断、治疗和潜在机制
DOI：
10.3389/fphar.2022.835510
复制
发表时间：
2022
影响因子：
5.6
通讯作者：
Wang, Jing
中科院分区：
文献类型：
--
作者：
Dong, Hao;Qi, Yihang;Kong, Xiangyi;Wang, Zhongzhao;Fang, Yi;Wang, Jing
免疫检查点抑制剂（ICI）诱导T细胞活化对抗癌细胞，由于其在多种癌症中的抗肿瘤功能，ICI已被认为是肿瘤治疗的重要选择。PD-1/PD-L1抑制剂目前在临床实践中广泛用作多种类型癌症的ICI。抗PD-1/PD-L1药物诱导的心肌炎并不常见，但显示出潜在的致命毒性。本文从T淋巴细胞浸润、调节性T细胞紊乱、细胞因子、巨噬细胞介导的炎症反应以及PD-1/PD-L1和CTLA 4的协同作用等方面，对PD-1/PD-L1和CTLA 4的发病机制、特点、诊断和治疗进行综述。
Immune checkpoint inhibitors (ICIs) induce T-cell activation against cancer cells, and due to their anti-tumor function in multiple cancers, ICIs have been considered an important option for oncotherapy. PD-1/PD-L1 inhibitors are now widely used as ICIs for many types of cancers in clinical practices. Myocarditis induced by anti-PD-1/PD-L1 agents is uncommon but shows potentially fatal toxicity. In this review, we attempted to conclude the incidence, characteristics, diagnosis, and treatments, as well as illustrate the potential pathogenesis from the perspectives of T-lymphocyte infiltration, disturbance of regulatory T cells, cytokines, macrophage-mediated inflammatory response, and synergistic effect of PD-1/PD-L1 and CTLA4.
登录
查看更多内容
T细胞共刺激和共抑制的分子机制。
DOI：
10.1038/nri3405
发表时间：
2013-04
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
通讯作者：
--
影响因子：
3.7
作者：
Bando S;Soeki T;Matsuura T;Tobiume T;Ise T;Kusunose K;Yamaguchi K;Yagi S;Fukuda D;Iwase T;Yamada H;Wakatsuki T;Shimabukuro M;Muguruma N;Takayama T;Kishimoto I;Kangawa K;Sata M
通讯作者：
Sata M
影响因子：
37.8
作者：
Ammirati, Enrico;Cipriani, Manlio;Frigerio, Maria
通讯作者：
Frigerio, Maria
影响因子：
7.5
作者：
Champion, Samantha N.;Stone, James R.
通讯作者：
Stone, James R.
影响因子：
3.3
作者：
Chen, Qiang;Huang, Dang-Sheng;Liu, Hong-bin
通讯作者：
Liu, Hong-bin